Lucentis (ranibizumab injection) is a prescription medicine developed by Genentech and the Novartis Ophthalmics Business Unit for the treatment of patients with wet age-related macular degeneration (AMD). Like other injections given into the eye, serious eye infection and detached retina have occurred with Lucentis. Increases in eye pressure have been seen within 60 minutes of an injection. Your eye doctor will monitor your eye pressure and eye health during the week after each and every injection. If your eye becomes red, sensitive to light, painful, or has a change in vision, you should seek immediate medical care from your eye doctor.

Lucentis Treatment

Lucentis is a humanized anti-VEGF antibody fragment that inhibits VEGF activity by competitively binding with VEGF. Lucentis is derived from Avastin, a full-length humanized monoclonal antibody against VEGF, and Genentech has developed Lucentis with a marketing tie-up with Novartis Ophthalmics.  Genentech is committed to facilitating timely reimbursement and assisting to minimize patient and practice burden through a full support program. Lucentis is injected inside the eye (intravitreous injection) as an office procedure that is best performed by Opthalmoslogist with speciality training in Retina and Vitreous surgery.

Degeneration Lucentis Macular

Wet macular degeneration is less frequent but more severe than the dry form.  It accounts for approximately 10% of all AMD but 90% of all blindness from the disease.  This form is characterized by choroidal neovascularization (CNV), the development of abnormal blood vessels beneath the retinal pigment epithelium (RPE) layer of the retina.  These vessels can bleed and in due course cause macular scarring, which can result in profound loss of central vision.